Clinical Edge Journal Scan

FPG measurements could help identify individuals at higher risk for future CRC


 

Key clinical point: The risk for incident colorectal cancer (CRC) events increases with the presence of normal-high fasting plasma glucose (FPG), impaired fasting glucose (IFG), and diabetes mellitus (DM).

Major finding: Compared with normal FPG, the presence of normal-high FPG (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03-1.18), IFG (HR, 1.24; 95% CI, 1.13-1.37), and DM (HR, 1.36; 95% CI, 1.19-1.55) was associated with a higher incidence rate of CRC.

Study details: Findings are from a retrospective observational study of 1,441,311 individuals who underwent annual health checkups. Included patients did not have colorectal polyps, Crohn's disease, and/or ulcerative colitis and were not taking antidiabetic medications.

Disclosures: The study was supported by grants from the Ministry of Health, Labour, and Welfare and the Ministry of Education, Culture, Sports, Science, and Technology, Japan. H Kaneko and K Fujiu declared receiving research funding and scholarship funds from various sources.

Source: Itoh H et al. J Clin Endocrinol Metab. 2021 Jun 25. doi: 10.1210/clinem/dgab466 .

Recommended Reading

Mutational signature may reveal underlying link between red meat and CRC
MDedge Hematology and Oncology
Good survival, outcomes with TARE for HCC in practice
MDedge Hematology and Oncology
Higher preoperative dietary fiber intake may reduce complications after CRC surgery
MDedge Hematology and Oncology
No benefit of adding pembrolizumab to neoadjuvant chemoradiotherapy in LARC
MDedge Hematology and Oncology
Survival correlates with response to preoperative chemotherapy in CRPM patients undergoing CRS/HIPEC
MDedge Hematology and Oncology
Efficacy of EGFR treatment for metastatic CRC differs with primary tumor location
MDedge Hematology and Oncology
Adherence to CRC screening programs essential even in asymptomatic average-risk individuals
MDedge Hematology and Oncology
Higher total vitamin D intake tied to reduced risk for early-onset CRC
MDedge Hematology and Oncology
No prognostic impact of primary tumor location in mCRC patients under later-line REG or FTD/TPI
MDedge Hematology and Oncology
Early-onset CRC may have survival benefits over late-onset CRC
MDedge Hematology and Oncology